Baseline characteristics of the total study population
| N = 5941 . | Total cohort, N (%) or mean ± SD . |
|---|---|
| Age (y) | 69.0 ± 8.1 |
| Female sex | 3401 (57.2%) |
| Smoking | |
| Current | 1020 (17.3%) |
| Former | 2907 (49.4%) |
| BMI (kg/m2) | 27.0 ± 4.1 |
| Use of antithrombotic medication | 952 (16.8%) |
| Use of antihypertensive drugs | 1314 (23.2%) |
| Use of lipid-reducing agents | 716 (12.6%) |
| Presence of diabetes mellitus | 599 (10.2%) |
| Total cholesterol (mg/dL)* | 224.7 ± 37.7 |
| HDL cholesterol (mg/dL)* | 53.8 ± 14.9 |
| Hypertension | |
| Systolic blood pressure (mm Hg) | 143 ± 21 |
| Diastolic blood pressure (mm Hg) | 77 ± 11 |
| Grade I hypertension | 2309 (39.1%) |
| Grade II hypertension | 879 (14.9%) |
| Blood group O | 2288 (45.3%) |
| ADAMTS13 activity (%) | 91.89 ± 17.8 |
| N = 5941 . | Total cohort, N (%) or mean ± SD . |
|---|---|
| Age (y) | 69.0 ± 8.1 |
| Female sex | 3401 (57.2%) |
| Smoking | |
| Current | 1020 (17.3%) |
| Former | 2907 (49.4%) |
| BMI (kg/m2) | 27.0 ± 4.1 |
| Use of antithrombotic medication | 952 (16.8%) |
| Use of antihypertensive drugs | 1314 (23.2%) |
| Use of lipid-reducing agents | 716 (12.6%) |
| Presence of diabetes mellitus | 599 (10.2%) |
| Total cholesterol (mg/dL)* | 224.7 ± 37.7 |
| HDL cholesterol (mg/dL)* | 53.8 ± 14.9 |
| Hypertension | |
| Systolic blood pressure (mm Hg) | 143 ± 21 |
| Diastolic blood pressure (mm Hg) | 77 ± 11 |
| Grade I hypertension | 2309 (39.1%) |
| Grade II hypertension | 879 (14.9%) |
| Blood group O | 2288 (45.3%) |
| ADAMTS13 activity (%) | 91.89 ± 17.8 |
SI conversion factors. To convert total cholesterol and HDL cholesterol to mmol/L, multiply values by 0.0259.